By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD268 ‒ Genetics: testing, therapy, editing, association with disease risk, autism, and more
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
At a glance
WHAT IT’S REALLY ABOUT
Wendy Chung on Genetic Testing, Gene Therapy, Editing, and Disease
- Chung explains that genetic tests differ in purpose: direct-to-consumer SNP tests like 23andMe and Ancestry are recreational or ancestry-oriented, while targeted panels, exomes and whole genomes answer medical questions with varying depth.
- She describes the GUARDIAN study, which sequences genes from newborn dried blood spots to screen for treatable rare diseases, with about 74% of approached parents opting in and a cost of roughly $1,000 per baby that she hopes to cut to $100.
- The conversation covers how gene therapy works, including the Jesse Gelsinger tragedy, viral vector immune risks, gene addition versus gene editing, and CRISPR's off-target limitations.
- Chung and Attia compare the genetic architecture of complex conditions, noting obesity heritability around 0.5, autism around 0.8 to 0.9 with hundreds of implicated genes, and cardiovascular disease where therapies may target a final common pathway such as PCSK9.
- They close on cost and ethics, covering $1–3 million gene therapies, the scientific consensus against germline editing and enhancement, and Chung's cautious outlook that diagnosis will become trivial by 2040 while therapeutic reach is uncertain.
IDEAS WORTH REMEMBERING
5 ideasNot all genetic tests serve the same purpose
Chung says 23andMe and Ancestry read selected SNPs for ancestry and recreational traits, so a clean result is not an all-clear for health. Medical tests are targeted to a specific question, and she advises a second opinion before irreversible decisions like a mastectomy.
Read depth guards against sequencing errors
Short reads of about 100 base pairs are error-prone, so each position is sequenced many times, typically around 30X. For somatic cancer mutations present in few cells, depth can reach 1,000X.
Newborn genomic screening can add to traditional screening
GUARDIAN pairs DNA sequencing with the dried blood spot already used for PKU, and it caught a baby with severe combined immunodeficiency that traditional screening missed. Chung notes children with these conditions are often not diagnosed until around eight to ten years old otherwise.
Gene therapy is promising but still in its infancy
Only a handful of conditions, such as SMA, have approved gene therapies, and immune responses to viral vectors remain a risk. Chung notes that some conditions, like Wilson disease, are treated cheaply with zinc once diagnosed early.
Different diseases need different genetic strategies
Recessive loss-of-function conditions like Tay-Sachs suit gene addition, while sickle cell and fragile X (a repeat expansion) call for gene editing. Delivery to the brain and the timing window of treatability are major hurdles.
WORDS WORTH SAVING
5 quotesI often tell people, you know, the first gene that I cloned took eight years, um, and you know, the last gene I cloned took eight hours. So, you know, this is just absolutely astronomically different in terms of how we now find disease genes.
— Wendy Chung
So although gene therapy is wonderful, I want to underscore we don't always need gene therapy, so long as we have that early diagnosis.
— Wendy Chung
We're all ninety-nine point nine percent the same. Um, about one in a thousand base pairs is what you and I probably differ, uh, by on average.
— Wendy Chung
I think it's very hard for me to predict timing. Um, and I think Bill Gates is, has a quote similar to this. You know, I do think within some point in the next hundred years we'll get to this point, whether it's the next twenty years or not
— Wendy Chung
It doesn't take much in society and in science to get us stuck.
— Wendy Chung
High quality AI-generated summary created from speaker-labeled transcript.
